These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-001563-21 A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia not-yet-due
Listed as ongoing, but also has a completion date and reported results 2005-000705-59 A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Epratuzumab in Patients with Acute Severe SLE Flares Excluding the Renal or Neurologic Systems 2007-03-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2005-000706-31 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus 2007-02-16 bad-data
Exempt 2008-000434-47 A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia not-yet-due
Exempt 2008-003993-16 A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer not-yet-due
Reported results 2013-004516-21 An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic ... 2016-03-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003019-21 An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Rece... 2020-12-03 bad-data
Ongoing 2018-001167-23 A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy Étude de phase II en ouvert de l’IMMU 132 da... not-yet-due
Other 2018-004201-33 Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negativ... not-yet-due
Ongoing 2019-004868-22 Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan. not-yet-due
Ongoing 2020-002964-29 A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer Studio randomi... not-yet-due